Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study
Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study
复制标题
DOI：
10.1016/s0920-1211(00)00180-7
复制
发表时间：
2000-12-01
影响因子：
2.2
通讯作者：
Brodie, MJ
中科院分区：
文献类型：
--
作者：
Kwan, P;Sills, GJ;Brodie, MJ
有轶事报道，谷氨酸脱羧酶（CAD）自身抗体升高的难治性癫痫患者。我们检测了105例原发性或症状性癫痫患者的血清GAD自身抗体。GAD自身抗体绝对滴度在癫痫控制组和未控制组之间无显著性差异。然而，四名患有不受控制的癫痫的女性患者的水平比无癫痫组中检测到的最高水平高出三倍以上，其中三人还检测出胰岛细胞抗体阳性。更大规模的研究，也许比较不同的癫痫综合征，需要确定确切的临床作用GAD自身抗体在癫痫。(C)2000爱思唯尔科学爱尔兰有限公司保留所有权利。
There have been anecdotal reports of raised glutamic acid decarboxylase (CAD) autoantibodies in patients with refractory epilepsy. We measured serum GAD autoantibodies in 105 patients with idiopathic or symptomatic epilepsy. There was no significant difference in the absolute titre of GAD autoantibody between patients with controlled and uncontrolled epilepsy. However, four female patients with uncontrolled epilepsy had levels that were over three times above the highest detected in the seizure-free group, three of whom also tested positive for pancreatic islet cell antibodies. Larger scale studies, perhaps comparing different epilepsy syndromes, are required to determine the exact clinical role of GAD autoantibodies in epilepsy. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.